Celecoxib (Celebrex) in the Management of Acute Renal Colic

Inclusion Criteria: * Ureteral calculus \<= 10 mm in largest diameter * Patient elects conservative management over immediate surgical intervention Exclusion Criteria: * Solitary kidney * Renal insufficiency (creatinine \[CR\] \> 1.8) * Urinary infection (fever \> 101 degrees Fahrenheit, positive urine culture, many bacteria on urinalysis) * Allergic-type reactions to sulfonamides * Patients with known hypersensitivity to celecoxib * Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or nonsteroidal anti-inflammatory agents (NSAIDs) * Prior history of gastrointestinal (GI) bleed or active gastric ulcer disease * Pregnancy/nursing * Moderate-severe hepatic dysfunction (Child-Pugh Classification B or C) * Concomitant use of drugs that inhibit P450 2C9, drugs metabolized by P450 2D6, ACE inhibitors, furosemide, warfarin (and other anticoagulants, not including low-dose aspirin), fluconazole, or lithium * Women of child-bearing age unwilling to use effective contraception for the duration of the trial. * Significant or unstable cardiovascular disease defined as: * myocardial infarction or stroke less than 3 months prior to the study randomization * planned revascularization (percutaneous coronary intervention \[PCI\] or coronary artery bypass surgery \[CABG\]) at the time of study screening * angina at rest or uncontrolled angina * hospitalization or emergency department visits for cardiac-related illness less than 3 months prior to randomization * uncontrolled hypertension (defined as systolic blood pressure \[BP\] \> 140 mmHg and/or diastolic BP \> 90 mmHg at the baseline visit) * evidence of cardiac electrophysiologic instability including history of uncontrolled complex ventricular arrhythmia, uncontrolled atrial fibrillation or flutter, or uncontrolled supraventricular tachycardias with a ventricular response heart rate of \> 100 beats per minute (BPM) at rest. (Subjects whose cardiac electrophysiologic instability is controlled with a pacemaker or implantable cardioverter defibrillator (ICD) are eligible.) * symptoms, signs or treatment for congestive heart failure (CHF) or known left ventricular dysfunction with ejection fraction \< 40% * undergone coronary bypass surgery or any major surgery (cardiac or noncardiac) or trauma within the past 3 months